Free Trial
→ While others chase AI stocks, smart traders do this (From WealthPress) (Ad) Buy LENZ Stock  Free LENZ Stock Alerts

LENZ Therapeutics (LENZ) Financials

LENZ Therapeutics logo
$29.53 +0.82 (+2.86%)
Closing price 04:00 PM Eastern
Extended Trading
$29.56 +0.02 (+0.08%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for LENZ Therapeutics

Annual Income Statements for LENZ Therapeutics

This table shows LENZ Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Income / (Loss) Attributable to Common Shareholders		 -50 -70 -101
Consolidated Net Income / (Loss)		 -50 -70 -101
Net Income / (Loss) Continuing Operations		 -50 -70 -101
Total Pre-Tax Income 		-50 -70 -101
Total Operating Income		 -59 -72 -106
Total Gross Profit		 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 59 72 106
Selling, General & Admin Expense		 29 13 33
Research & Development Expense		 30 60 73
Total Other Income / (Expense), net		 8.84 2.28 4.59
Interest & Investment Income		 8.55 2.19 -
Other Income / (Expense), net		 0.29 0.09 4.59
Income Tax Expense		 0.00 -0.18 -
Basic Earnings per Share		 ($2.34) ($35.71) ($1.84)
Weighted Average Basic Shares Outstanding		 21.28M 1.96M 54.87M
Diluted Earnings per Share		 ($2.34) ($35.71) ($1.84)
Weighted Average Diluted Shares Outstanding		 21.28M 1.96M 54.87M
Weighted Average Basic & Diluted Shares Outstanding		 27.54M 58.24M 58.16M

Quarterly Income Statements for LENZ Therapeutics

This table shows LENZ Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -15 -13 -10 -10 -17 -24 -19 -15 -13 -25 -25
Consolidated Net Income / (Loss)		 -15 -13 -10 -10 -17 -24 -19 -15 -13 -25 -25
Net Income / (Loss) Continuing Operations		 -15 -13 -10 -10 -17 -24 -19 -15 -13 -24 -25
Total Pre-Tax Income 		-15 -13 -10 -10 -17 -24 -19 -15 -13 -24 -25
Total Operating Income		 -17 -15 -13 -14 -16 -25 -20 -15 -13 -27 -26
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 17 15 13 14 16 25 20 15 13 27 26
Selling, General & Admin Expense		 11 9.36 6.49 7.41 5.55 5.45 2.86 2.32 2.29 8.29 7.85
Research & Development Expense		 5.82 5.87 6.45 6.95 11 20 17 13 10 18 18
Total Other Income / (Expense), net		 2.31 2.57 2.73 4.10 -0.56 1.12 0.99 0.23 -0.05 2.28 1.47
Interest & Investment Income		 2.32 2.57 2.74 2.46 0.79 0.85 1.09 0.25 0.00 - -
Other Income / (Expense), net		 -0.01 0.01 -0.01 1.64 -1.35 0.27 -0.10 -0.02 -0.05 2.28 1.47
Basic Earnings per Share		 ($0.53) $1.97 ($0.38) ($0.40) ($3.53) ($12.06) ($9.62) ($7.53) ($6.50) ($0.43) ($0.45)
Weighted Average Basic Shares Outstanding		 27.53M 21.28M 27.17M 25.61M 4.72M 1.96M 1.96M 1.96M 1.95M 54.87M 55.21M
Diluted Earnings per Share		 ($0.53) $1.97 ($0.38) ($0.40) ($3.53) ($12.06) ($9.62) ($7.53) ($6.50) ($0.43) ($0.45)
Weighted Average Diluted Shares Outstanding		 27.53M 21.28M 27.17M 25.61M 4.72M 1.96M 1.96M 1.96M 1.95M 54.87M 55.21M
Weighted Average Basic & Diluted Shares Outstanding		 28.15M 27.54M 27.50M 27.50M 25.53M 58.24M 58.00M 57.98M 58.10M 58.16M 58.15M

Annual Cash Flow Statements for LENZ Therapeutics

This table details how cash moves in and out of LENZ Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Change in Cash & Equivalents		 -15 -9.30 -329
Net Cash From Operating Activities		 -59 -60 -88
Net Cash From Continuing Operating Activities		 -59 -60 -88
Net Income / (Loss) Continuing Operations		 -50 -70 -101
Consolidated Net Income / (Loss)		 -50 -70 -101
Depreciation Expense		 0.06 0.02 2.35
Amortization Expense		 -4.02 -1.06 -1.60
Non-Cash Adjustments To Reconcile Net Income		 7.43 1.41 20
Changes in Operating Assets and Liabilities, net		 -13 9.41 -7.30
Net Cash From Investing Activities		 -154 -30 -242
Net Cash From Continuing Investing Activities		 -154 -30 -242
Purchase of Property, Plant & Equipment		 -0.47 -0.03 -6.59
Purchase of Investments		 -242 -52 -406
Sale and/or Maturity of Investments		 88 23 170
Net Cash From Financing Activities		 199 81 0.60
Net Cash From Continuing Financing Activities		 199 81 0.60
Repurchase of Common Equity		 0.00 -2.48 -0.08
Issuance of Preferred Equity		 0.00 83 -
Issuance of Common Equity		 80 0.00 0.66
Other Financing Activities, net		 119 0.20 0.02

Quarterly Cash Flow Statements for LENZ Therapeutics

This table details how cash moves in and out of LENZ Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 2.88 -21 -43 -116 165 -7.71 -32 -40 70 -8.66 -19
Net Cash From Operating Activities		 -16 -9.08 -11 -16 -24 -21 -13 -14 -13 -22 -22
Net Cash From Continuing Operating Activities		 -16 -9.08 -11 -16 -24 -21 -13 -14 -13 -22 -22
Net Income / (Loss) Continuing Operations		 -15 -13 -10 -10 -17 -24 -19 -15 -13 -25 -25
Consolidated Net Income / (Loss)		 -15 -13 -10 -10 -17 -24 -19 -15 -13 -25 -25
Depreciation Expense		 0.04 0.03 0.01 0.02 0.01 0.00 0.00 0.00 0.00 0.68 0.65
Amortization Expense		 -1.13 -1.42 -1.36 -0.96 -0.28 -0.51 -0.53 -0.02 0.00 -1.12 -0.56
Non-Cash Adjustments To Reconcile Net Income		 2.56 1.65 2.19 1.60 1.99 0.44 0.60 0.21 0.16 5.53 4.62
Changes in Operating Assets and Liabilities, net		 -2.97 3.33 -1.21 -6.20 -9.01 2.98 5.72 1.00 -0.29 -2.92 -2.24
Net Cash From Investing Activities		 19 -12 -62 -98 18 15 -18 -27 -0.01 14 3.50
Net Cash From Continuing Investing Activities		 19 -12 -62 -98 18 15 -18 -27 -0.01 14 3.50
Purchase of Property, Plant & Equipment		 -0.11 -0.15 -0.19 -0.13 0.00 - - -0.02 -0.01 -1.02 -0.92
Purchase of Investments		 -33 -47 -84 - - -5.83 -19 - - -66 -86
Sale and/or Maturity of Investments		 52 35 22 13 18 21 1.50 - 0.00 80 90
Net Cash From Financing Activities		 0.04 0.05 30 -2.14 171 -1.91 -0.57 - 83 0.24 -0.06
Net Cash From Continuing Financing Activities		 0.04 0.05 30 -2.14 171 -1.91 -0.57 - 83 0.24 -0.06
Issuance of Common Equity		 0.00 -0.09 30 -3.56 53 - - - 0.00 0.24 -
Other Financing Activities, net		 0.04 0.14 0.04 1.43 118 - - - 0.20 0.00 0.01

Annual Balance Sheets for LENZ Therapeutics

This table presents LENZ Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Total Assets		 215 70 322
Total Current Assets		 212 67 275
Cash & Equivalents		 20 35 48
Restricted Cash		 0.11 0.00 0.00
Short-Term Investments		 189 31 220
Prepaid Expenses		 2.77 1.45 7.14
Plant, Property, & Equipment, net		 0.65 0.05 23
Total Noncurrent Assets		 2.74 3.08 24
Other Noncurrent Operating Assets		 2.74 3.08 8.59
Total Liabilities & Shareholders' Equity		 215 70 322
Total Liabilities		 11 20 26
Total Current Liabilities		 10 19 13
Accounts Payable		 4.26 5.71 2.61
Accrued Expenses		 6.15 13 2.59
Total Noncurrent Liabilities		 0.81 1.18 13
Other Noncurrent Operating Liabilities		 0.81 1.18 13
Commitments & Contingencies		 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 0.00 143 0.00
Total Equity & Noncontrolling Interests		 204 -93 296
Total Preferred & Common Equity		 204 -93 296
Total Common Equity		 204 -93 296
Common Stock		 349 2.53 540
Retained Earnings		 -145 -95 -242
Accumulated Other Comprehensive Income / (Loss)		 0.20 0.01 -1.05

Quarterly Balance Sheets for LENZ Therapeutics

This table presents LENZ Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 201 224 203 217 266 287 310 335
Total Current Assets		 198 221 199 217 239 251 270 298
Cash & Equivalents		 23 41 84 200 183 129 70 56
Restricted Cash		 0.11 0.11 0.11 0.11 - - - -
Short-Term Investments		 171 176 112 13 51 118 194 235
Prepaid Expenses		 3.77 3.48 3.12 3.28 4.78 2.88 6.21 6.81
Plant, Property, & Equipment, net		 0.93 0.37 0.16 0.05 13 18 33 13
Total Noncurrent Assets		 2.47 2.93 3.13 0.60 15 18 6.62 23
Other Noncurrent Operating Assets		 2.47 2.93 3.13 0.60 15 18 6.62 9.68
Total Liabilities & Shareholders' Equity		 201 224 203 217 266 287 310 335
Total Liabilities		 9.24 8.73 9.72 19 62 63 34 18
Total Current Liabilities		 8.57 7.71 8.58 19 13 12 14 14
Accounts Payable		 3.66 2.76 4.41 7.13 3.75 2.72 1.99 3.97
Accrued Expenses		 4.91 4.95 4.18 12 3.45 4.37 7.91 1.65
Total Noncurrent Liabilities		 0.67 1.02 1.14 0.27 50 51 19 4.87
Other Noncurrent Operating Liabilities		 0.67 1.02 1.14 0.27 50 51 19 4.87
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 192 215 193 198 204 224 276 316
Total Preferred & Common Equity		 192 215 193 198 204 224 276 316
Total Common Equity		 192 215 193 198 204 224 276 316
Common Stock		 352 347 315 310 548 546 543 536
Retained Earnings		 -160 -132 -122 -112 -344 -322 -266 -218
Accumulated Other Comprehensive Income / (Loss)		 0.12 0.52 -0.06 -0.00 -0.10 -0.27 -0.47 -1.60

Annual Metrics And Ratios for LENZ Therapeutics

This table displays calculated financial ratios and metrics derived from LENZ Therapeutics' official financial filings.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Growth Metrics		 - - -
Revenue Growth		 0.00% 0.00% 0.00%
EBITDA Growth		 15.12% 26.84% -43.23%
EBIT Growth		 19.37% 28.42% -42.81%
NOPAT Growth		 19.08% 31.44% -74.77%
Net Income Growth		 28.87% 30.76% -42.81%
EPS Growth		 93.45% -1,840.76% 24.90%
Operating Cash Flow Growth		 1.64% 31.37% -66.46%
Free Cash Flow Firm Growth		 -123.61% 71.31% -0.77%
Invested Capital Growth		 66.53% -218.65% 80.10%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 47.32% -0.43% -6.72%
EBIT Q/Q Growth		 51.46% -0.34% -5.81%
NOPAT Q/Q Growth		 55.31% 2.38% -7.98%
Net Income Q/Q Growth		 56.51% 1.28% -33.54%
EPS Q/Q Growth		 -113.64% -48.30% -132.74%
Operating Cash Flow Q/Q Growth		 41.14% 2.36% -8.42%
Free Cash Flow Firm Q/Q Growth		 57.37% -115.89% 0.00%
Invested Capital Q/Q Growth		 -160.69% 49.59% 12.10%
Profitability Metrics		 - - -
Gross Margin		 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 99.74% 100.00%
Interest Burden Percent		 85.33% 96.97% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -39.07% -40.33% -29.71%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -803.61%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -17.08% -23.66% -29.71%
Return on Equity Simple (ROE_SIMPLE)		 -24.39% 75.47% -34.11%
Net Operating Profit after Tax (NOPAT)		 -41 -51 -74
NOPAT Margin		 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -6.36% -11.03% -8.21%
Return On Investment Capital (ROIC_SIMPLE)		 -20.10% 54.69% -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -58 -72 -101
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -62 -73 -100
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 3.89 0.00 0.65
Price to Tangible Book Value (P/TBV)		 3.89 0.00 0.65
Price to Revenue (P/Rev)		 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -1.08 -1.01 -0.97
Leverage Ratio		 1.12 1.13 1.06
Compound Leverage Factor		 0.96 1.10 1.06
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 282.94% 0.00%
Common Equity to Total Capital		 100.00% -182.94% 100.00%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 41.74 0.17 3.41
Noncontrolling Interest Sharing Ratio		 56.28% 41.33% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 20.36 3.63 21.11
Quick Ratio		 20.09 3.55 20.57
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -51 -23 -80
Operating Cash Flow to CapEx		 -12,690.38% -201,266.67% -1,334.24%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 -5.06 -15 13
Invested Capital Turnover		 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 10 -28 5.67
Enterprise Value (EV)		 585 230 -90
Market Capitalization		 794 152 193
Book Value per Share		 $7.42 ($1.60) $5.10
Tangible Book Value per Share		 $7.42 ($1.60) $5.10
Total Capital		 204 51 296
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -209 -66 -284
Capital Expenditures (CapEx)		 0.47 0.03 6.59
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -7.63 -17 -5.91
Debt-free Net Working Capital (DFNWC)		 202 49 262
Net Working Capital (NWC)		 202 49 262
Net Nonoperating Expense (NNE)		 8.74 19 27
Net Nonoperating Obligations (NNO)		 -209 -66 -284
Total Depreciation and Amortization (D&A)		 -3.96 -1.04 0.75
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($2.34) ($2.19) ($1.84)
Adjusted Weighted Average Basic Shares Outstanding		 21.28M 57.02M 54.87M
Adjusted Diluted Earnings per Share		 ($2.34) ($2.19) ($1.84)
Adjusted Weighted Average Diluted Shares Outstanding		 21.28M 57.02M 54.87M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 27.54M 58.24M 58.16M
Normalized Net Operating Profit after Tax (NOPAT)		 -41 -51 -74
Normalized NOPAT Margin		 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -3.54% -0.08%

Quarterly Metrics And Ratios for LENZ Therapeutics

This table displays calculated financial ratios and metrics derived from LENZ Therapeutics' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -1.89% 34.14% 30.21% 8.90% -39.78% -1.26% 16.68% 40.79% 50.27% -33.95% -70.85%
EBIT Growth		 2.83% 38.45% 35.13% 15.09% -37.62% -1.01% 19.11% 42.25% 51.19% -29.30% -69.15%
NOPAT Growth		 -5.24% 39.07% 34.84% 4.06% -27.52% 6.59% 24.05% 44.13% 51.40% -41.24% -79.11%
Net Income Growth		 12.19% 46.60% 45.90% 30.37% -31.40% 3.69% 23.51% 43.22% 50.96% -3,257.77% -69.15%
EPS Growth		 84.99% 116.34% 96.05% 94.69% 45.69% -2,704.65% -2,037.78% -1,468.75% -1,254.17% -106.12% -60.71%
Operating Cash Flow Growth		 32.95% 56.71% 19.16% -16.79% -87.04% 6.51% 41.09% 38.79% 39.75% -43.84% -44.13%
Free Cash Flow Firm Growth		 -255.34% -299.87% -235.20% -229.50% 236.73% 142.49% 212.05% 174.89% 56.98% 0.00% -59.05%
Invested Capital Growth		 86.34% 66.53% 93.53% 86.31% -225.54% -218.65% -363.85% -337.29% 31.97% 80.10% 119.44%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -8.57% -16.20% -4.70% 22.86% 74.49% -23.14% -36.67% -18.35% 49.16% -1.31% 2.88%
EBIT Q/Q Growth		 -11.34% -17.50% -1.84% 27.06% 76.60% -23.83% -33.31% -18.21% 48.24% 0.83% 4.84%
NOPAT Q/Q Growth		 -11.21% -17.61% 9.80% 10.79% 80.52% -25.79% -32.80% -18.57% 52.84% -2.28% 2.32%
Net Income Q/Q Growth		 -15.55% -23.86% 0.38% 38.41% 77.47% -25.49% -28.21% -16.23% 48.49% 0.34% 4.84%
EPS Q/Q Growth		 -126.90% 618.42% 5.00% 88.67% -128.86% -25.36% -27.76% -15.85% -1,411.63% 4.44% 6.25%
Operating Cash Flow Q/Q Growth		 -76.79% 14.20% 33.01% 34.01% 47.82% -60.22% 3.22% -5.67% 42.94% -0.95% -0.56%
Free Cash Flow Firm Q/Q Growth		 -20.68% 44.18% -20.13% -291.94% 153.72% -62.24% 15.07% 302.66% 51.75% 0.42% 23.09%
Invested Capital Q/Q Growth		 58.89% -160.69% 41.27% 78.29% -0.73% 49.59% -24.19% -299.10% -4.80% 12.10% 11.68%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.01% 100.00% 100.00% 100.00% 99.25% 100.00% 100.00% 100.00% 100.50% 100.00%
Interest Burden Percent		 86.29% 83.14% 78.87% 80.63% 95.48% 96.55% 94.56% 98.32% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -24.47% -39.07% -54.59% -59.04% -53.79% -40.33% -27.23% -27.26% -27.57% -29.71% -21.12%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -633.70% -803.61% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -24.47% -17.08% -54.59% -59.04% -53.79% -23.66% -27.23% -27.26% -27.57% -29.71% -21.12%
Return on Equity Simple (ROE_SIMPLE)		 -24.86% 0.00% -53.16% -63.81% -64.38% 0.00% -34.74% -34.21% -31.82% 0.00% -23.91%
Net Operating Profit after Tax (NOPAT)		 -12 -11 -9.06 -10 -11 -17 -14 -10 -8.83 -19 -18
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.36% -1.45% -0.51% -0.09% -2.26% -3.55% -1.85% -1.48% -1.25% -1.78% -1.82%
Return On Investment Capital (ROIC_SIMPLE)		 -6.17% -5.22% - - - 18.87% - - - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -17 -15 -13 -13 -17 -25 -20 -15 -13 -24 -25
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -18 -17 -14 -14 -18 -25 -20 -15 -13 -25 -25
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.69 3.89 3.03 2.29 6.54 0.00 0.70 0.67 0.52 0.65 0.58
Price to Tangible Book Value (P/TBV)		 3.69 3.89 3.03 2.29 6.54 0.00 0.70 0.67 0.52 0.65 0.58
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.04 -1.08 -1.08 -1.07 -1.01 -1.01 -1.04 -1.02 -0.97 -0.97 -0.98
Leverage Ratio		 1.07 1.12 1.17 1.17 1.11 1.13 1.15 1.14 1.08 1.06 1.05
Compound Leverage Factor		 0.93 0.93 0.92 0.95 1.06 1.09 1.09 1.12 1.08 1.06 1.05
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 282.94% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% -182.94% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 45.71 42.40 45.00 27.34 40.67 2.41 0.35 0.70 2.18 4.20 5.89
Noncontrolling Interest Sharing Ratio		 0.00% 56.28% 0.00% 0.00% 0.00% 41.33% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 23.09 20.36 28.63 23.23 11.47 3.63 19.05 20.47 18.85 21.11 22.07
Quick Ratio		 22.64 20.09 28.16 22.85 11.29 3.55 18.66 20.10 18.42 20.57 21.57
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -25 -21 -37 -31 16 10 27 24 -12 -24 -24
Operating Cash Flow to CapEx		 -14,590.00% -6,092.62% -5,688.71% -11,875.94% 0.00% 0.00% 0.00% -56,350.00% -213,300.00% -2,196.77% -2,428.09%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -2.08 -5.06 -1.94 -3.31 -15 -15 -30 -24 12 13 11
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 13 10 28 21 -27 -28 -41 -34 2.94 5.67 6.19
Enterprise Value (EV)		 514 585 436 245 1,082 230 -90 -96 -122 -90 -121
Market Capitalization		 708 794 653 441 1,295 152 144 151 143 193 185
Book Value per Share		 $6.97 $7.42 $7.83 $7.56 $42.01 ($1.60) $3.52 $3.86 $4.75 $5.10 $5.44
Tangible Book Value per Share		 $6.97 $7.42 $7.83 $7.56 $42.01 ($1.60) $3.52 $3.86 $4.75 $5.10 $5.44
Total Capital		 192 204 215 193 198 51 204 224 276 296 316
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -194 -209 -217 -196 -213 -66 -234 -247 -264 -284 -305
Capital Expenditures (CapEx)		 0.11 0.15 0.19 0.13 0.00 0.00 0.00 0.02 0.01 1.02 0.92
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.80 -7.63 -4.23 -5.46 -16 -17 -7.74 -7.76 -8.13 -5.91 -6.72
Debt-free Net Working Capital (DFNWC)		 189 202 213 191 198 49 226 239 256 262 285
Net Working Capital (NWC)		 189 202 213 191 198 49 226 239 256 262 285
Net Nonoperating Expense (NNE)		 2.77 1.99 1.15 0.21 5.39 6.20 4.97 4.25 3.84 5.87 6.37
Net Nonoperating Obligations (NNO)		 -194 -209 -217 -196 -213 -66 -234 -248 -264 -284 -305
Total Depreciation and Amortization (D&A)		 -1.10 -1.40 -1.35 -0.94 -0.27 -0.51 -0.52 -0.02 0.00 -0.44 0.09
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.53) $1.97 ($0.38) ($0.40) ($3.53) ($12.06) ($0.39) ($0.97) ($0.43) ($0.43) ($0.45)
Adjusted Weighted Average Basic Shares Outstanding		 27.53M 21.28M 27.17M 25.61M 4.72M 1.96M 57.26M 56.75M 55.86M 54.87M 55.21M
Adjusted Diluted Earnings per Share		 ($0.53) $1.97 ($0.38) ($0.40) ($3.53) ($12.06) ($0.39) ($0.97) ($0.43) ($0.43) ($0.45)
Adjusted Weighted Average Diluted Shares Outstanding		 27.53M 21.28M 27.17M 25.61M 4.72M 1.96M 57.26M 56.75M 55.86M 54.87M 55.21M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 28.15M 27.54M 27.50M 27.50M 25.53M 58.24M 58.00M 57.98M 58.10M 58.16M 58.15M
Normalized Net Operating Profit after Tax (NOPAT)		 -12 -11 -9.06 -10 -11 -17 -14 -10 -8.83 -19 -18
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.44% 0.00% 0.00% -3.54% 0.00% 0.00% 0.00% -0.08% 0.00%

Frequently Asked Questions About LENZ Therapeutics' Financials

When does LENZ Therapeutics's financial year end?

According to the most recent income statement we have on file, LENZ Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has LENZ Therapeutics' net income changed over the last 2 years?

LENZ Therapeutics' net income appears to be on a downward trend, with a most recent value of -$49.77 million in 2024, falling from -$101.05 million in 2022. The previous period was -$69.97 million in 2023. See where experts think LENZ Therapeutics is headed by visiting LENZ Therapeutics' forecast page.

What is LENZ Therapeutics's operating income?
LENZ Therapeutics's total operating income in 2024 was -$58.61 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $58.61 million
How has LENZ Therapeutics revenue changed over the last 2 years?

Over the last 2 years, LENZ Therapeutics' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does LENZ Therapeutics have?

LENZ Therapeutics' total liabilities were at $11.22 million at the end of 2024, a 43.0% decrease from 2023, and a 56.2% decrease since 2022.

How much cash does LENZ Therapeutics have?

In the past 2 years, LENZ Therapeutics' cash and equivalents has ranged from $20.16 million in 2024 to $47.73 million in 2022, and is currently $20.16 million as of their latest financial filing in 2024.

How has LENZ Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, LENZ Therapeutics' book value per share changed from 5.10 in 2022 to 7.42 in 2024, a change of 45.6%.


Related Companies

This page (NASDAQ:LENZ) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...
Premier Gold Co | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...
Colonial Metals | Sponsored
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...
Stansberry Research | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...
Paradigm Press | Sponsored